Salflucombi Easyhaler 50 mikrogram/500 mikrogram/dos Inhalationspulver

Država: Švedska

Jezik: švedščina

Source: Läkemedelsverket (Medical Products Agency)

Aktivna sestavina:

flutikasonpropionat; salmeterolxinafoat

Dostopno od:

Orion Corporation

Koda artikla:

R03AK06

INN (mednarodno ime):

fluticasone propionate; salmeterol

Odmerek:

50 mikrogram/500 mikrogram/dos

Farmacevtska oblika:

Inhalationspulver

Sestava:

laktosmonohydrat Hjälpämne; salmeterolxinafoat 73 mikrog Aktiv substans; flutikasonpropionat 500 mikrog Aktiv substans

Tip zastaranja:

Receptbelagt

Povzetek izdelek:

Förpacknings: Inhalator, 1 x 60 doser (utan fodral); Inhalator, 2 x 60 doser (utan fodral); Inhalator, 3 x 60 doser (utan fodral); Inhalator, 1 x 60 doser (med fodral); Inhalator, 2 x 60 doser (med fodral); Inhalator, 3 x 60 doser (med fodral)

Status dovoljenje:

Godkänd

Datum dovoljenje:

2018-06-15

Navodilo za uporabo

1
PACKAGE LEAFLET
2
QR code to www.oeh.fi/ xxxx [to be completed nationally].
Scan this code or visit www.oeh.fi/ xxxx [to be completed nationally]
to see instructions on how to use
Easyhaler
PACKAGE LEAFLET: INFORMATION FOR THE USER
Salflucombi Easyhaler 50 microgram/500 microgram/dose, inhalation
powder
Salmeterol/fluticasone propionate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Salflucombi Easyhaler is and what it is used for
2.
What you need to know before you use Salflucombi Easyhaler
3.
How to use Salflucombi Easyhaler
4.
Possible side effects
5.
How to store Salflucombi Easyhaler
6.
Contents of the pack and other information
1.
WHAT SALFLUCOMBI EASYHALER IS AND WHAT IT IS USED FOR
Salflucombi Easyhaler contains two medicines, salmeterol and
fluticasone propionate:
•
Salmeterol is a long-acting bronchodilator. Bronchodilators help the
airways in the lungs to stay
open. This makes it easier for air to get in and out. The effects last
for at least 12 hours.
•
Fluticasone propionate is a corticosteroid which reduces swelling and
irritation in the lungs.
The doctor has prescribed this medicine to help prevent breathing
problems such as:
•
Asthma
•
Chronic Obstructive Pulmonary Disease (COPD). Salflucombi Easyhaler,
at a dose of
50/500 micrograms, reduces the number of flare ups of COPD symptoms.
3
You must use Salflucombi Easyhaler every day as directed by your
doctor. This will make sure that it
works properly in controlling your asthma or COPD.
Salflucombi Easyhaler helps to s

Lastnosti izdelka

1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Salflucombi Easyhaler 50 microgram/500 microgram/dose, inhalation
powder
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Salflucombi Easyhaler 50 microgram/500 microgram: Each delivered dose
(the dose that leaves the
mouthpiece) contains salmeterol xinafoate corresponding to 48
micrograms of salmeterol and
476 micrograms fluticasone propionate.
This corresponds to a metered dose of salmeterol xinafoate
corresponding to 50 micrograms of
salmeterol and 500 micrograms fluticasone propionate.
Excipient with known effect: Lactose monohydrate 17 mg per delivered
dose
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder
White powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_ASTHMA_
Salflucombi Easyhaler is indicated in the regular treatment of asthma
where use of a combination
product
_ _
(long-acting

2
agonist
_ _
and inhaled corticosteroid) is
_ _
appropriate:
-
patients not adequately controlled with inhaled corticosteroids and
‘as needed’ inhaled short-
acting

2
agonist
or
-
patients already adequately controlled on both inhaled corticosteroid
and long-acting

2
agonist.
_CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)_
Salflucombi Easyhaler is indicated for the symptomatic treatment of
patients with COPD, with a FEV
1
<60% predicted normal (pre-bronchodilator) and a history of repeated
exacerbations, who have
significant symptoms despite regular bronchodilator therapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Patients should be made aware that Salflucombi Easyhaler must be used
daily for optimum benefit,
even when asymptomatic.
3
Patients should be regularly reassessed by a doctor, so that the
strength of salmeterol/fluticasone
propionate inhaler they are receiving remains optimal
_ _
and is only changed on medical advice.
THE
DOSE SHOULD BE TITRATED TO THE LOWEST DOSE AT WHICH EFFECTIVE CONTROL
OF SYMPTOMS IS MAINTAINED.
Salflucombi Easyhaler is not available on the market at